Moderna’s (NASDAQ: MRNA) CEO, Stephane Bancel, announced Thursday that the company should have an answer as to whether its coronavirus vaccine is successful or not by November.
“If the infection rate in the country were to slow down in the next weeks, it could potentially be pushed out in a worst-case scenario in December,” Bancel added.
The Massachusetts-based biotechnology company is one of the few drugmakers endorsed by the U.S in its late-stage testing for trial coronavirus vaccine. The other two companies are Pfizer and AstraZeneca.
With the potential vaccine containing genetic components called messenger RNA or mRNA, scientists are hopeful that it will stimulate the immune system to battle the virus. The company released data in June exhibiting possible positive results within a small number of patients.
Bancel’s news follows a recent announcement from Pfizer that its vaccine could be available to Americans by the end of 2020. Pfizer CEO, Albert Bourla, revealed that upon FDA approval the company is ready to administer “hundreds of thousands of doses.”
However, there has been strong concern that the White House could be pressuring the FDA to authorize a vaccine as President Trump announced there could be an approved vaccine as early as October.
“We believe this is unprecedented times. There’s a lot of suffering from a public health standpoint,” Bancel said Thursday. “If Moderna’s vaccine were to get a good safety readout and a good efficacy readout and be approved by the agency, we care deeply that this vaccine is trusted.”